No Data
No Data
Earnings Scheduled For February 13, 2025
Smaller Biotechs See New Mechanisms of Actions as Future of Obesity Treatments
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $40
Stifel Nicolaus Reaffirms Their Buy Rating on MBX Biosciences, Inc. (MBX)
MBX Biosciences Director Makes Bold Stock Move
Insider Purchase: President & CEO of $MBX Buys 50,000 Shares
Unlock the Full List